Dale Lange, MD
Neurology · New York, NYNPI 1528038841
Payments from drug & device makers
Across 218 payments — averaging $4072.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$413K
- Novartis$128K
- Takeda Pharmaceuticals U.S.A., Inc.$93K
- Orion Corporation$93K
- AstraZeneca$65K
- CSL Behring$33K
- plus $62K from 11 others
Across 5 payments — averaging $1149.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$5K
- AstraZeneca$546
What the payments were for
- Consulting fees$10,80070%
- Speaking & faculty fees$9006%
- Travel & lodging$2,54017%
- Food & beverage$1,1197%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 56 | $413,374 |
| Novartis | 2 | $127,849 |
| Takeda Pharmaceuticals U.S.A., Inc. | 58 | $92,927 |
| Orion Corporation | 13 | $92,906 |
| AstraZeneca | 33 | $65,488 |
| CSL Behring | 28 | $33,119 |
| Argenx US, Inc. | 6 | $20,256 |
| Amgen | 3 | $17,100 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 6 | $16,861 |
| Apellis Pharmaceuticals, Inc. | 1 | $3,675 |
| UCB Biosciences Inc. | 3 | $2,150 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 4 | $935 |
| Janssen Research & Development, LLC | 1 | $900 |
| UCB, Inc. | 1 | $150 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hizentra$2,895
How this compares
$887,738 in reported general payments places this provider in the 95th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 60 | $837,841 |
| SolirisEculizumab | 14 | $725,898 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 12 | $443,868 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $354,374 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 15 | $345,202 |
| Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-50 | 14 | $243,006 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 22 | $242 |
| Prednisone | 15 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $14 | $837,84160 claims |
| AstraZenecaSoliris | $65,488 | $725,89814 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $92,927 | $354,37413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,623 neurology providers in New York.
Other neurology in New York
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Sheng-Han KuoNew York$3.2M
- Stephen KriegerNew York$3.1M
- Thomas KaleyNew York$2.9M
- Aaron MillerNew York$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.